This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Bebee TW, Dominguez CE, Chandler DS. Mouse models of SMA: Tools for disease characterization and therapeutic development. Hum Genet. 2012; 131: 1277–1293.BebeeTWDominguezCEChandlerDSMouse models of SMA: Tools for disease characterization and therapeutic developmentHum Genet.20121311277129310.1007/s00439-012-1171-522543872Search in Google Scholar
Willis TA. Therapeutic advances in spinal muscular atrophy. Paediatr Child Heal (United Kingdom). 2019; 29: 463–467.WillisTATherapeutic advances in spinal muscular atrophyPaediatr Child Heal (United Kingdom).20192946346710.1016/j.paed.2019.07.009Search in Google Scholar
Dangouloff T, Botty C, Beaudart C, Servais L, Hiligsmann M. Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments. Orphanet J Rare Dis. 2021; 16: 47.DangouloffTBottyCBeaudartCServaisLHiligsmannMSystematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatmentsOrphanet J Rare Dis.2021164710.1186/s13023-021-01695-7782491733485382Search in Google Scholar
Monani UR, Lorson CL, Parsons DW, Prior TW, Androphy EJ, Burghes AHM, McPherson JD. A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum. Mol Genet. 1999; 8: 1177–1183.MonaniURLorsonCLParsonsDWPriorTWAndrophyEJBurghesAHMMcPhersonJDA single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2Hum. Mol Genet.199981177118310.1093/hmg/8.7.117710369862Search in Google Scholar
Schorling DC, Pechmann A, Kirschner J. Advances in treatment of spinal muscular atrophy - new phenotypes, new challenges, new implications for care. J Neuromuscul Dis. 2020; 7: 1–13.SchorlingDCPechmannAKirschnerJAdvances in treatment of spinal muscular atrophy - new phenotypes, new challenges, new implications for careJ Neuromuscul Dis.2020711310.3233/JND-190424702931931707373Search in Google Scholar
Tisdale S, Pellizzoni L. Disease mechanisms and therapeutic approaches in spinal muscular atrophy. J Neurosci. 2015; 35: 8691–8700.TisdaleSPellizzoniLDisease mechanisms and therapeutic approaches in spinal muscular atrophyJ Neurosci.2015358691870010.1523/JNEUROSCI.0417-15.2015446168226063904Search in Google Scholar
Feldkötter M, Schwarzer V, Wirth R, Wienker TF, Wirth B. Quantitative analyses of SMN1 and SMN2 based on real-time lightcycler PCR: Fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet. 2002; 70: 358–368.FeldkötterMSchwarzerVWirthRWienkerTFWirthBQuantitative analyses of SMN1 and SMN2 based on real-time lightcycler PCR: Fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophyAm J Hum Genet.20027035836810.1086/33862741998711791208Search in Google Scholar
Bebee TW, Gladman JT, Chandler DS. Splicing of the survival motor neuron genes and implications for treatment of SMA. Front Biosci. 2010; 15: 1191–1204.BebeeTWGladmanJTChandlerDSSplicing of the survival motor neuron genes and implications for treatment of SMAFront Biosci.2010151191120410.2741/3670292169620515750Search in Google Scholar
Cartegni L, Krainer AR. Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN. Nat Genet. 2002; 30: 377–384.CartegniLKrainerARDisruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMNNat Genet.20023037738410.1038/ng85411925564Search in Google Scholar
Russman BS. Spinal muscular atrophy: Clinical classification and disease heterogeneity. J Child Neurol. 2007; 22: 946–951.RussmanBSSpinal muscular atrophy: Clinical classification and disease heterogeneityJ Child Neurol.20072294695110.1177/088307380730567317761648Search in Google Scholar
Maretina MA, Zheleznyakova GY, Lanko KM, Egorova AA, Baranov VS, Kiselev AV. Molecular factors involved in spinal muscular atrophy pathways as possible disease-modifying candidates. Curr Genomics. 2018; 19: 339–355.MaretinaMAZheleznyakovaGYLankoKMEgorovaAABaranovVSKiselevAVMolecular factors involved in spinal muscular atrophy pathways as possible disease-modifying candidatesCurr Genomics.20181933935510.2174/1389202919666180101154916603085930065610Search in Google Scholar
Farrar MA, Kiernan MC. The genetics of spinal muscular atrophy: Progress and challenges. Neurotherapeutics. 2015; 12: 290–302.FarrarMAKiernanMCThe genetics of spinal muscular atrophy: Progress and challengesNeurotherapeutics.20151229030210.1007/s13311-014-0314-x440444125413156Search in Google Scholar
Khorkova O, Wahlestedt C. Oligonucleotide therapies for disorders of the nervous system. Nat Biotechnol. 2017; 35: 249–263.KhorkovaOWahlestedtCOligonucleotide therapies for disorders of the nervous systemNat Biotechnol.20173524926310.1038/nbt.3784604390028244991Search in Google Scholar
Li Q. Nusinersen as a therapeutic agent for spinal muscular atrophy. Yonsei Med J. 2020; 61: 273–283.LiQNusinersen as a therapeutic agent for spinal muscular atrophyYonsei Med J.20206127328310.3349/ymj.2020.61.4.273710540732233169Search in Google Scholar
Chiriboga CA, Swoboda KJ, Darras BT, Iannaccone ST, Montes J, De Vivo DC, Norris DA, Bennett CF, Bishop KM. Results from a phase 1 study of nusinersen (ISIS-SMN Rx) in children with spinal muscular atrophy. Neurology, 2016; 86: 890–897.ChiribogaCASwobodaKJDarrasBTIannacconeSTMontesJDe VivoDCNorrisDABennettCFBishopKMResults from a phase 1 study of nusinersen (ISIS-SMN Rx) in children with spinal muscular atrophyNeurology20168689089710.1212/WNL.0000000000002445478211126865511Search in Google Scholar
Goodkey K, Aslesh T, Maruyama R, Yokota T. Nusinersen in the treatment of spinal muscular atrophy. Methods Mol Biol. 2018; 1828: 69–76.GoodkeyKAsleshTMaruyamaRYokotaTNusinersen in the treatment of spinal muscular atrophyMethods Mol Biol.20181828697610.1007/978-1-4939-8651-4_430171535Search in Google Scholar
Hoy SM. Nusinersen: First global approval. Drugs, 2017; 77: 473–479.HoySMNusinersen: First global approvalDrugs20177747347910.1007/s40265-017-0711-728229309Search in Google Scholar
Ramdas S, Servais L. New treatments in spinal muscular atrophy: An overview of currently available data. Expert Opin Pharmacother. 2020; 21: 307–315.RamdasSServaisLNew treatments in spinal muscular atrophy: An overview of currently available dataExpert Opin Pharmacother.20202130731510.1080/14656566.2019.170473231973611Search in Google Scholar
Finkel RS, Chiriboga CA, Vajsar J, Day JW, Montes J, De Vivo DC, Yamashita M, Rigo F, Hung G, Schneider E, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: A phase 2, open-label, dose-escalation study. Lancet, 2016; 388: 3017–3026.FinkelRSChiribogaCAVajsarJDayJWMontesJDe VivoDCYamashitaMRigoFHungGSchneiderETreatment of infantile-onset spinal muscular atrophy with nusinersen: A phase 2, open-label, dose-escalation studyLancet20163883017302610.1016/S0140-6736(16)31408-827939059Search in Google Scholar
De Vivo DC, Bertini E, Swoboda KJ, Hwu WL, Crawford TO, Finkel RS, Kirschner J, Kuntz NL, Parsons JA, Ryan MM, et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul Disord. 2019; 29: 842–856.De VivoDCBertiniESwobodaKJHwuWLCrawfordTOFinkelRSKirschnerJKuntzNLParsonsJARyanMMNusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE studyNeuromuscul Disord.20192984285610.1016/j.nmd.2019.09.007712728631704158Search in Google Scholar
Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, Iannaccone ST, Kirschner J, Kuntz NL, Saito K, et al. Nusinersen versus Sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018; 378: 625–635.MercuriEDarrasBTChiribogaCADayJWCampbellCConnollyAMIannacconeSTKirschnerJKuntzNLSaitoKNusinersen versus Sham control in later-onset spinal muscular atrophyN Engl J Med.201837862563510.1056/NEJMoa171050429443664Search in Google Scholar
AveXis Inc. ZOLGENSMA® US product information 2019 [https://www.fda.gov/vaccines-blood-biologics/zolgensma] accessed 09.02.2021.AveXis Inc. ZOLGENSMA®US product information 2019[https://www.fda.gov/vaccines-blood-biologics/zolgensma] accessed 09.02.2021.Search in Google Scholar
National Institute for Health Research. AVXS-101 for spinal muscular atrophy. 2018 [http://www.io.nihr.ac.uk/report/avxs-101-for-spinal-muscular-atrophy/] accessed 09.02.2021.National Institute for Health ResearchAVXS-101 for spinal muscular atrophy2018[http://www.io.nihr.ac.uk/report/avxs-101-for-spinal-muscular-atrophy/] accessed 09.02.2021.Search in Google Scholar
Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, Lowes L, Alfano L, Berry K, Church K, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017; 377: 1713–1722.MendellJRAl-ZaidySShellRArnoldWDRodino-KlapacLRPriorTWLowesLAlfanoLBerryKChurchKSingle-dose gene-replacement therapy for spinal muscular atrophyN Engl J Med.20173771713172210.1056/NEJMoa170619829091557Search in Google Scholar
Malone DC, Dean R, Arjunji R, Jensen I, Cyr P, Miller B, Maru B, Sproule DM, Feltner DE, Dabbous O. Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients. J Mark Access Heal Policy, 2019; 7: 1601484.MaloneDCDeanRArjunjiRJensenICyrPMillerBMaruBSprouleDMFeltnerDEDabbousOCost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patientsJ Mark Access Heal Policy20197160148410.1080/20016689.2019.1601484650805831105909Search in Google Scholar
Roche. Roche announces 2-year risdiplam data from SUNFISH and new data from JEWELFISH in infants, children and adults with spinal muscular atrophy (SMA) 2020 [media release] [https://www.roche.com/media/releases/med-cor-2020-06-12.htm] accessed 20.02.2021.RocheRoche announces 2-year risdiplam data from SUNFISH and new data from JEWELFISH in infants, children and adults with spinal muscular atrophy (SMA)2020[media release] [https://www.roche.com/media/releases/med-cor-2020-06-12.htm] accessed 20.02.2021.Search in Google Scholar
Drug Trials Snapshots: EVRYSDI. US product information. 2020 [https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-evrysdi] accessed 20.02.2021.Drug Trials Snapshots: EVRYSDIUS product information2020[https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-evrysdi] accessed 20.02.2021.Search in Google Scholar
Servais L, Baranello G, Day JW, Deconinck N, Mercuri E, Klein A, Darras B, Masson R, Kletzl H, Cleary Y, et al. FIREFISH Part 1: Survival, ventilation and swallowing ability in infants with Type 1 SMA receiving risdiplam (RG7916). 2019.ServaisLBaranelloGDayJWDeconinckNMercuriEKleinADarrasBMassonRKletzlHClearyYFIREFISH Part 1: Survival, ventilation and swallowing ability in infants with Type 1 SMA receiving risdiplam (RG7916)2019Search in Google Scholar
Servais L, Baranello G, Masson R, Mazurkiewicz-Bełdzińska M, Rose K, Vlodavets D, Xiong H, Zanoteli E, El-Khairi M, Fuerst-Recktenwald S, et al. FIREFISH Part 2: Efficacy and safety of risdiplam (RG7916) in infants with type 1 spinal muscular atrophy (SMA).ServaisLBaranelloGMassonRMazurkiewicz-BełdzińskaMRoseKVlodavetsDXiongHZanoteliEEl-KhairiMFuerst-RecktenwaldSFIREFISH Part 2: Efficacy and safety of risdiplam (RG7916) in infants with type 1 spinal muscular atrophy (SMA)Search in Google Scholar
Dhillon S. Risdiplam: First approval. Drugs, 2020; 80: 1853–1858.DhillonSRisdiplam: First approvalDrugs2020801853185810.1007/s40265-020-01410-z33044711Search in Google Scholar
Chiriboga CA, Bruno C, Duong T, Fischer D, Kirschner J, Mercuri E, Carruthers I, Gerber M, Gorni K, Kletzl H, et al. JEWELFISH: Safety and pharmacodynamic data in non-naïve patients with spinal muscular atrophy (SMA) receiving treatment with risdiplam.ChiribogaCABrunoCDuongTFischerDKirschnerJMercuriECarruthersIGerberMGorniKKletzlHJEWELFISH: Safety and pharmacodynamic data in non-naïve patients with spinal muscular atrophy (SMA) receiving treatment with risdiplamSearch in Google Scholar
Cheung AK, Hurley B, Kerrigan R, Shu L, Chin DN, Shen Y, O'Brien G, Sung MJ, Hou Y, Axford J, et al. Discovery of small molecule splicing modulators of survival motor neuron-2 (SMN2) for the treatment of spinal muscular atrophy (SMA). J Med Chem. 2018; 61: 11021–11036.CheungAKHurleyBKerriganRShuLChinDNShenYO'BrienGSungMJHouYAxfordJDiscovery of small molecule splicing modulators of survival motor neuron-2 (SMN2) for the treatment of spinal muscular atrophy (SMA)J Med Chem.201861110211103610.1021/acs.jmedchem.8b0129130407821Search in Google Scholar
Palacino J, Swalley SE, Song C, Cheung AK, Shu L, Zhang X, Van Hoosear M, Shin Y, Chin DN, Keller CG, et al. SMN2 splice modulators enhance U1-pre-mRNA association and rescue SMA mice. Nat Chem Biol. 2015; 11: 511–517.PalacinoJSwalleySESongCCheungAKShuLZhangXVan HoosearMShinYChinDNKellerCGSMN2 splice modulators enhance U1-pre-mRNA association and rescue SMA miceNat Chem Biol.20151151151710.1038/nchembio.183726030728Search in Google Scholar
Russell AJ, Hartman JJ, Hinken AC, Muci AR, Kawas R, Driscoll L, Godinez G, Lee KH, Marquez D, Browne IV WF, et al. Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseases. Nat Med. 2012; 18: 452–455.RussellAJHartmanJJHinkenACMuciARKawasRDriscollLGodinezGLeeKHMarquezDBrowneWFIVActivation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseasesNat Med.20121845245510.1038/nm.2618329682522344294Search in Google Scholar
Andrews JA, Miller TM, Vijayakumar V, Stoltz R, James JK, Meng L, Wolff AA, Malik FI. CK-2127107 amplifies skeletal muscle response to nerve activation in humans. Muscle Nerve, 2018; 57: 729–734.AndrewsJAMillerTMVijayakumarVStoltzRJamesJKMengLWolffAAMalikFICK-2127107 amplifies skeletal muscle response to nerve activation in humansMuscle Nerve20185772973410.1002/mus.26017668106529150952Search in Google Scholar
Pirruccello-Straub M, Jackson J, Wawersik S, Webster MT, Salta L, Long K, McConaughy W, Capili A, Boston C, Carven GJ, et al. Blocking extracellular activation of myostatin as a strategy for treating muscle wasting. Sci Rep. 2018; 8: 2292.Pirruccello-StraubMJacksonJWawersikSWebsterMTSaltaLLongKMcConaughyWCapiliABostonCCarvenGJBlocking extracellular activation of myostatin as a strategy for treating muscle wastingSci Rep.20188229210.1038/s41598-018-20524-9579720729396542Search in Google Scholar
Dagbay KB, Treece E, Streich FC, Jackson JW, Faucette RR, Nikiforov A, Lin SC, Boston CJ, Nicholls SB, Capili AD, Carven GJ. Structural basis of specific inhibition of extracellular activation of pro- or latent myostatin by the monoclonal antibody SRK-015. J Biol Chem. 2020; 295: 5404–5418.DagbayKBTreeceEStreichFCJacksonJWFaucetteRRNikiforovALinSCBostonCJNichollsSBCapiliADCarvenGJStructural basis of specific inhibition of extracellular activation of pro- or latent myostatin by the monoclonal antibody SRK-015J Biol Chem.20202955404541810.1074/jbc.RA119.012293717053232075906Search in Google Scholar
Long KK, O'Shea KM, Khairallah RJ, Howell K, Paushkin S, Chen KS, Cote SM, Webster MT, Stains JP, Treece E, et al. Specific inhibition of myostatin activation is beneficial in mouse models of SMA therapy. Hum Mol Genet. 2019; 28: 1076–1089.LongKKO'SheaKMKhairallahRJHowellKPaushkinSChenKSCoteSMWebsterMTStainsJPTreeceESpecific inhibition of myostatin activation is beneficial in mouse models of SMA therapyHum Mol Genet.2019281076108910.1093/hmg/ddy382642342030481286Search in Google Scholar
Xiao WH, Zheng FY, Bennett GJ, Bordet T, Pruss RM. Olesoxime (cholest-4-en-3-one, oxime): Analgesic and neuroprotective effects in a rat model of painful peripheral neuropathy produced by the chemotherapeutic agent, paclitaxel. Pain, 2009; 147: 202–209.XiaoWHZhengFYBennettGJBordetTPrussRMOlesoxime (cholest-4-en-3-one, oxime): Analgesic and neuroprotective effects in a rat model of painful peripheral neuropathy produced by the chemotherapeutic agent, paclitaxelPain200914720220910.1016/j.pain.2009.09.006278791019833436Search in Google Scholar
Muntoni F, Bertini E, Comi G, Kirschner J, Lusakowska A, Mercuri E, Scoto M, van der Pol WL, Vuillerot C, Burdeska A, et al. Long-term follow-up of patients with type 2 and non-ambulant type 3 spinal muscular atrophy (SMA) treated with olesoxime in the OLEOS trial. Neuromuscul Disord. 2020; 30: 959–969.MuntoniFBertiniEComiGKirschnerJLusakowskaAMercuriEScotoMvan der PolWLVuillerotCBurdeskaALong-term follow-up of patients with type 2 and non-ambulant type 3 spinal muscular atrophy (SMA) treated with olesoxime in the OLEOS trialNeuromuscul Disord.20203095996910.1016/j.nmd.2020.10.00833246887Search in Google Scholar
Bertini E, Dessaud E, Mercuri E, Muntoni F, Kirschner J, Reid C, Lusakowska A, Comi GP, Cuisset JM, Abitbol JL, et al. Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: A randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017; 16: 513–522.BertiniEDessaudEMercuriEMuntoniFKirschnerJReidCLusakowskaAComiGPCuissetJMAbitbolJLSafety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: A randomised, double-blind, placebo-controlled phase 2 trialLancet Neurol.20171651352210.1016/S1474-4422(17)30085-628460889Search in Google Scholar
Ratni H, Karp GM, Weetall M, Naryshkin NA, Paushkin SV, Chen KS, McCarthy KD, Qi H, Turpoff A, Woll MG, et al. Specific correction of alternative survival motor neuron 2 splicing by small molecules: Discovery of a potential novel medicine to treat spinal muscular atrophy. J Med Chem, 2016; 59: 6086–6100.RatniHKarpGMWeetallMNaryshkinNAPaushkinSVChenKSMcCarthyKDQiHTurpoffAWollMGSpecific correction of alternative survival motor neuron 2 splicing by small molecules: Discovery of a potential novel medicine to treat spinal muscular atrophyJ Med Chem2016596086610010.1021/acs.jmedchem.6b0045927299419Search in Google Scholar
Kletzl H, Marquet A, Günther A, Tang W, Heuberger J, Groeneveld GJ, Birkhoff W, Mercuri E, Lochmüller H, Wood C, et al. The oral splicing modifier RG7800 increases full length survival of motor neuron 2 mRNA and survival of motor neuron protein: Results from trials in healthy adults and patients with spinal muscular atrophy. Neuromuscul Disord. 2019; 29: 21–29.KletzlHMarquetAGüntherATangWHeubergerJGroeneveldGJBirkhoffWMercuriELochmüllerHWoodCThe oral splicing modifier RG7800 increases full length survival of motor neuron 2 mRNA and survival of motor neuron protein: Results from trials in healthy adults and patients with spinal muscular atrophyNeuromuscul Disord.201929212910.1016/j.nmd.2018.10.00130553700Search in Google Scholar
Ratni H, Ebeling M, Baird J, Bendels S, Bylund J, Chen KS, Denk N, Feng Z, Green L, Guerard M, et al. Discovery of Risdiplam, a selective survival of motor neuron-2 (SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA). J Med Chem. 2018; 61: 6501–6517.RatniHEbelingMBairdJBendelsSBylundJChenKSDenkNFengZGreenLGuerardMDiscovery of Risdiplam, a selective survival of motor neuron-2 (SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA)J Med Chem.2018616501651710.1021/acs.jmedchem.8b0074130044619Search in Google Scholar
Van Meerbeke JP, Gibbs RM, Plasterer HL, Miao W, Feng Z, Lin MY, Rucki AA, Wee CD, Xia B, Sharma S, et al. The DcpS inhibitor RG3039 improves motor functionin SMA mice. Hum Mol Genet. 2013; 22: 4074–4083.Van MeerbekeJPGibbsRMPlastererHLMiaoWFengZLinMYRuckiAAWeeCDXiaBSharmaSThe DcpS inhibitor RG3039 improves motor functionin SMA miceHum Mol Genet.2013224074408310.1093/hmg/ddt257378163723727836Search in Google Scholar
Gogliotti RG, Cardona H, Jasbir S, Bail S, Emery C, Kuntz N, Jorgensen M, Durens Madel M, Xia B, Barlow C, et al. The dcpS inhibitor RG3039 improves survival, function and motor unit pathologies in two SMA mouse models. Hum Mol Genet. 2013; 22: 4084–4101.GogliottiRGCardonaHJasbirSBailSEmeryCKuntzNJorgensenMDurens MadelMXiaBBarlowCThe dcpS inhibitor RG3039 improves survival, function and motor unit pathologies in two SMA mouse modelsHum Mol Genet.2013224084410110.1093/hmg/ddt258378163823736298Search in Google Scholar
Mohseni J, Zabidi-Hussin ZAMH, Sasongko TH. Histone deacetylase inhibitors as potential treatment for spinal muscular atrophy. Genet Mol Biol. 2013; 36: 299–307.MohseniJZabidi-HussinZAMHSasongkoTHHistone deacetylase inhibitors as potential treatment for spinal muscular atrophyGenet Mol Biol.20133629930710.1590/S1415-47572013000300001379517324130434Search in Google Scholar
Swoboda KJ, Scott CB, Reyna SP, Prior TW, LaSalle B, Sorenson SL, Wood J, Acsadi G, Crawford TO, Kissel JT, et al. Phase II open label study of valproic acid in spinal muscular atrophy. PLoS One, 2009; 4: e5268.SwobodaKJScottCBReynaSPPriorTWLaSalleBSorensonSLWoodJAcsadiGCrawfordTOKisselJTPhase II open label study of valproic acid in spinal muscular atrophyPLoS One20094e526810.1371/journal.pone.0005268268003419440247Search in Google Scholar
Swoboda KJ, Scott CB, Crawford TO, Simard LR, Reyna SP, Krosschell KJ, Acsadi G, Elsheik B, Schroth MK, D'Anjou G, et al. SMA CARNI-VAL trial part I: Double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy. PLoS One, 2010; 5: e12140.SwobodaKJScottCBCrawfordTOSimardLRReynaSPKrosschellKJAcsadiGElsheikBSchrothMKD'AnjouGSMA CARNI-VAL trial part I: Double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophyPLoS One20105e1214010.1371/journal.pone.0012140292437620808854Search in Google Scholar
Kissel JT, Scott CB, Reyna SP, Crawford TO, Simard LR, Krosschell KJ, Acsadi G, Elsheik B, Schroth MK, D'Anjou G, et al. SMA CARNI-VAL TRIAL PART II: A prospective, single-armed trial of L-carnitine and valproic acid in ambulatory children with spinal muscular atrophy. PLoS One, 2011; 6: e21296.KisselJTScottCBReynaSPCrawfordTOSimardLRKrosschellKJAcsadiGElsheikBSchrothMKD'AnjouGSMA CARNI-VAL TRIAL PART II: A prospective, single-armed trial of L-carnitine and valproic acid in ambulatory children with spinal muscular atrophyPLoS One20116e2129610.1371/journal.pone.0021296313073021754985Search in Google Scholar
Kissel JT, Elsheikh B, King WM, Freimer M, Scott CB, Kolb SJ, Reyna SP, Crawford TO, Simard LR, Krosschell KJ, et al. SMA valiant trial: A prospective, double-blind, placebo-controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy. Muscle Nerve. 2014; 49: 187–192.KisselJTElsheikhBKingWMFreimerMScottCBKolbSJReynaSPCrawfordTOSimardLRKrosschellKJSMA valiant trial: A prospective, double-blind, placebo-controlled trial of valproic acid in ambulatory adults with spinal muscular atrophyMuscle Nerve.20144918719210.1002/mus.23904388883323681940Search in Google Scholar
Ojala KS, Reedich EJ, DiDonato CJ. Meriney SD. In search of a cure: The development of therapeutics to alter the progression of spinal muscular atrophy. Brain Sci. 2021; 11: 194.OjalaKSReedichEJDiDonatoCJMerineySDIn search of a cure: The development of therapeutics to alter the progression of spinal muscular atrophyBrain Sci.20211119410.3390/brainsci11020194791583233562482Search in Google Scholar
Hjorth E, Kreicbergs U, Sejersen T, Lövgren M. Parents' advice to healthcare professionals working with children who have spinal muscular atrophy. Eur J Paediatr Neurol. 2018; 22: 128–134.HjorthEKreicbergsUSejersenTLövgrenMParents' advice to healthcare professionals working with children who have spinal muscular atrophyEur J Paediatr Neurol.20182212813410.1016/j.ejpn.2017.10.00829146237Search in Google Scholar
López-Bastida J, Peña-Longobardo LM, Aranda-Reneo I, Tizzano E, Sefton M, Oliva-Moreno J. Social/economic costs and health-related quality of life in patients with spinal muscular atrophy (SMA) in Spain. Orphanet J Rare Dis. 2017; 12: 141.López-BastidaJPeña-LongobardoLMAranda-ReneoITizzanoESeftonMOliva-MorenoJSocial/economic costs and health-related quality of life in patients with spinal muscular atrophy (SMA) in SpainOrphanet J Rare Dis.20171214110.1186/s13023-017-0695-0556303528821278Search in Google Scholar
Qian Y, McGraw S, Henne J, Jarecki J, Hobby K, Yeh WS. Understanding the experiences and needs of individuals with Spinal Muscular Atrophy and their parents: A qualitative study. BMC Neurol., 2015; 15: 217.QianYMcGrawSHenneJJareckiJHobbyKYehWSUnderstanding the experiences and needs of individuals with Spinal Muscular Atrophy and their parents: A qualitative studyBMC Neurol.20151521710.1186/s12883-015-0473-3461951326499462Search in Google Scholar
Tejero R, Balk S, Franco-Espin J, Ojeda J, Hennlein L, Drexl H, Dombert B, Clausen JD, Torres-Benito L, Saal-Bauernschubert L, et al. R-Roscovitine improves motoneuron function in mouse models for spinal muscular atrophy. iScience, 2020; 23: 100826.TejeroRBalkSFranco-EspinJOjedaJHennleinLDrexlHDombertBClausenJDTorres-BenitoLSaal-BauernschubertLR-Roscovitine improves motoneuron function in mouse models for spinal muscular atrophyiScience20202310082610.1016/j.isci.2020.100826699299631981925Search in Google Scholar
Sansone VA, Pirola A, Albamonte E, Pane M, Lizio A, D'Amico A, Catteruccia M, Cutrera R, Bruno C, Pedemonte M, et al. Respiratory needs in patients with type 1 spinal muscular atrophy treated with nusinersen. J Pediatr. 2020; 219: 223–228.e4.SansoneVAPirolaAAlbamonteEPaneMLizioAD'AmicoACatterucciaMCutreraRBrunoCPedemonteMRespiratory needs in patients with type 1 spinal muscular atrophy treated with nusinersenJ Pediatr.2020219223228.e410.1016/j.jpeds.2019.12.04732035635Search in Google Scholar
Cruz R, Belter L, Wasnock M, Nazarelli A, Jarecki J. Evaluating benefit-risk decision-making in spinal muscular atrophy: A first-ever study to assess risk tolerance in the SMA patient community. Clin Ther. 2019; 41: 943–960.e4.CruzRBelterLWasnockMNazarelliAJareckiJEvaluating benefit-risk decision-making in spinal muscular atrophy: A first-ever study to assess risk tolerance in the SMA patient communityClin Ther.201941943960.e410.1016/j.clinthera.2019.03.01231056304Search in Google Scholar